Solventum (NYSE:SOLV) Updates FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 6.600-6.600 for the period, compared to the consensus earnings per share estimate of 6.470. The company issued revenue guidance of -.

Solventum Trading Up 0.9%

Shares of SOLV traded up $0.62 during mid-day trading on Thursday, reaching $71.61. The company’s stock had a trading volume of 1,698,539 shares, compared to its average volume of 1,271,732. The stock has a market cap of $12.40 billion, a PE ratio of 11.38, a P/E/G ratio of 1.15 and a beta of 0.59. The company has a current ratio of 1.07, a quick ratio of 0.89 and a debt-to-equity ratio of 0.96. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The company’s fifty day moving average price is $67.88 and its two-hundred day moving average price is $74.51.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts predict that Solventum will post 6.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SOLV has been the subject of a number of recent research reports. Rothschild & Co Redburn initiated coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective for the company. Piper Sandler lowered their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. KeyCorp lifted their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday. Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $89.00 target price on shares of Solventum in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $85.91.

Insider Activity at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the purchase, the director directly owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.24% of the stock is currently owned by insiders.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q1 beat and strong guidance signals — Solventum reported Q1 EPS $1.48 vs. $1.35 est. and revenue $2.01B vs. $1.97B; management said FY2026 profit should come in at the higher end of the prior $6.40–$6.60 range, driven by wound care and sterilization demand. Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management signals improving margins — Earnings call and analyst summaries highlight margin momentum and operational leverage ahead, supporting the higher-end guidance. Solventum Earnings Call Signals Margin Momentum Ahead
• Positive Sentiment: Investor access: management will present at the BofA Health Care Conference next week, giving investors a chance for direct Q&A and color on execution. Solventum to Participate in the 2026 BofA Securities Health Care Conference
• Neutral Sentiment: Technical and momentum commentary — Several outlets note SOLV recently broke above its 20- and 50-day moving averages and is a long-term momentum candidate; these are technical positives but not new fundamentals. Solventum (SOLV) Recently Broke Out Above the 20-Day Moving Average
• Neutral Sentiment: Analyst reinforcement — BTIG reaffirmed a Buy with an $89 PT (bullish, longer-term upside), adding support to the rally. Solventum (NYSE:SOLV) Receives “Buy” Rating from BTIG Research
• Negative Sentiment: Tariff headwinds flagged — Management expects $100M–$120M of annual tariff-related pressure, which could compress margins or require pricing adjustments. Solventum outlines EPS toward high end of $6.40-$6.60 range while expecting $100M-$120M annual tariff headwinds
• Negative Sentiment: Price-target cut from Wells Fargo — Wells Fargo lowered its PT to $70 and moved to Equal Weight, which could cap near-term upside and weighs on sentiment despite the beat. Wells Fargo price target cut (Benzinga)

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BOKF NA increased its position in Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares during the period. Smartleaf Asset Management LLC increased its position in Solventum by 23.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock valued at $60,000 after purchasing an additional 142 shares during the period. Lazard Asset Management LLC increased its position in Solventum by 1.4% during the 2nd quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock valued at $880,000 after purchasing an additional 163 shares during the period. Orion Porfolio Solutions LLC increased its position in Solventum by 0.7% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 24,295 shares of the company’s stock valued at $1,843,000 after purchasing an additional 176 shares during the period. Finally, Lido Advisors LLC increased its position in Solventum by 2.3% during the 4th quarter. Lido Advisors LLC now owns 7,899 shares of the company’s stock valued at $583,000 after purchasing an additional 178 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.